Summary

Market Overview
The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification.
Key Market Drivers
The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB’s diverse etiologies. NCFB’s chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase.
Key Market Challenges
The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.
Key Market Trends
The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate.
Key Market Players
• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy’s Laboratories Ltd.
Report Scope:
In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:
o Surgery
o Physiotherapy
o Vaccination
o Airway pharmacotherapy
o Antibiotics
o Others
• Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:
o CT scan
o Bronchoscopy
o Chest X-ray
o Lung function
o Sputum culture test
o Blood tests
o Others
• Non-Cystic Fibrosis Bronchiectasis Market, By End use:
o Hospitals & Clinics
o Ambulatory Care Centers
o Others
• Non-Cystic Fibrosis Bronchiectasis Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.
Available Customizations:
Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Cystic Fibrosis Bronchiectasis Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Surgery, Physiotherapy, Vaccination, Airway pharmacotherapy, Antibiotics, Others)
5.2.2. By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others)
5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Non-Cystic Fibrosis Bronchiectasis Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By Diagnosis
6.2.3. By End use
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By Diagnosis
6.3.1.2.3. By End use
6.3.2. Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By Diagnosis
6.3.2.2.3. By End use
6.3.3. Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By Diagnosis
6.3.3.2.3. By End use
7. Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By Diagnosis
7.2.3. By End use
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By End use
7.3.2. France Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By End use
7.3.3. United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By End use
7.3.4. Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By Diagnosis
7.3.4.2.3. By End use
7.3.5. Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By Diagnosis
7.3.5.2.3. By End use
8. Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By Diagnosis
8.2.3. By End use
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By End use
8.3.2. India Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By End use
8.3.3. Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By End use
8.3.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By End use
8.3.5. Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By End use
9. Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By Diagnosis
9.2.3. By End use
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By End use
9.3.2. UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By End use
9.3.3. South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By End use
10. South America Non-Cystic Fibrosis Bronchiectasis Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By Diagnosis
10.2.3. By End use
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By End use
10.3.2. Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By End use
10.3.3. Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By End use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Novartis AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Bayer AG
15.4. Viatris Inc.
15.5. Teva Pharmaceutical Industries Ltd.
15.6. GSK plc
15.7. F. Hoffmann-La Roche Ltd.
15.8. Sun Pharmaceutical Industries Ltd.
15.9. Aurobindo Pharma Ltd.
15.10. Dr. Reddy’s Laboratories Ltd.
16. Strategic Recommendations
17. About Us & Disclaimer